5-Amino-1MQ: The NNMT Inhibitor and What It Actually Does

5-Amino-1MQ shows up in the same conversations as peptides, but it is not a peptide. It is a small molecule — a quinolinium compound — that works by blocking a specific enzyme called nicotinamide N-methyltransferase (NNMT). The reason it has attracted attention in the body-composition community is a 2021 Nature Communications paper showing significant fat reduction in obese mice, without caloric restriction, and a mechanistic story connecting NNMT inhibition to NAD+ metabolism and fat cell biology.

The animal data is genuinely interesting. The human data is essentially absent. Understanding the gap between those two things is what this piece is about.

What NNMT does and why it matters

NNMT catalyzes the methylation of nicotinamide (a form of vitamin B3) to produce 1-methylnicotinamide. This reaction consumes methyl groups and depletes the cellular pool of nicotinamide that would otherwise be available as a precursor to NAD+.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to energy metabolism, DNA repair, and the activity of sirtuins — a family of proteins that regulate metabolism, gene expression, and cellular stress responses. SIRT1, the best-studied sirtuin, activates metabolic pathways including fatty acid oxidation and mitochondrial biogenesis when NAD+ is abundant.

The connection: high NNMT activity depletes nicotinamide → less NAD+ → less SIRT1 activity → impaired fat metabolism. Blocking NNMT with 5-amino-1MQ theoretically reverses this, raising NAD+ availability and restoring metabolic function.

NNMT is highly expressed in adipose tissue. Studies in humans show NNMT expression correlates positively with obesity, insulin resistance, and type 2 diabetes — suggesting the enzyme is not a bystander in metabolic dysfunction but an active contributor.

The 2021 animal study

The most-cited preclinical study (Guan et al., Nature Communications, 2021, from the University of Texas) used diet-induced obese mice — a standard metabolic disease model. Key findings:

• Mice treated with 5-amino-1MQ showed significantly less body weight gain compared to controls, despite eating a high-fat diet
• Adipose tissue mass was reduced, particularly visceral fat
• NAD+ and SAM (S-adenosylmethionine) levels were elevated in treated animals, consistent with the proposed mechanism
• Insulin sensitivity improved in treated mice
• No significant toxic effects were observed over the study duration

The effect sizes were notable. Treated mice gained substantially less weight over the study period, and the improvement in insulin sensitivity was measurable.

Earlier work from the same research group (Neelakantan et al., 2019) showed 5-amino-1MQ reduced adiposity and improved the metabolic profile in obese mice, providing an independent replication within the same laboratory.

What the mechanistic picture looks like

Beyond the single study, there is a broader mechanistic picture that makes 5-amino-1MQ interesting:

NAD+ as a metabolic lever. The NMN and NR supplementation space has established significant public interest in raising NAD+ for metabolic and longevity purposes. 5-Amino-1MQ approaches the same endpoint (higher NAD+) from the upstream side — preventing its depletion rather than adding precursors. Whether blocking depletion is more effective than adding precursors is not established.

Fat cell differentiation. NNMT inhibition appears to reduce adipocyte differentiation — the process by which precursor cells become fat cells — in addition to its effects on existing fat metabolism. This adds a second pathway for fat reduction beyond pure lipolysis.

Methylation economics. The NNMT pathway consumes methyl groups. High NNMT activity in obese tissue essentially wastes methyl donors (SAM) on a metabolically unproductive reaction. Inhibiting NNMT frees up those methyl donors for other reactions, which may have effects beyond NAD+ metabolism. The full downstream picture of chronic NNMT inhibition in humans is not mapped.

What we don't know about human use

This is the largest section because it is the most important.

No published human trials. As of early 2026, there are no published clinical trials of 5-amino-1MQ in humans. Everything known about human use comes from self-reported community experience and the extrapolation of rodent data.

Rodent-to-human translation is uncertain. The gap between rodent obesity models and human obesity is well-documented. Multiple compounds that produced significant fat loss in diet-induced obese mice failed to produce meaningful effects in human trials. HGH fragment 176-191 (covered elsewhere on this site) is a recent example. The 5-amino-1MQ mouse data is consistent and mechanistically coherent, but this does not guarantee human efficacy.

Long-term NNMT inhibition effects are unknown. NNMT has functions across multiple tissues beyond adipose. Inhibiting it systemically over months or years could have effects on liver function, immune activity, and the broader methylation cycle that have not been characterized. Short-term rodent studies do not establish long-term safety in humans.

NAD+ supplementation interactions. Many people interested in 5-amino-1MQ are also taking NMN or NR for NAD+ support. Whether combining an NNMT inhibitor (which raises NAD+ by blocking depletion) with NAD+ precursors produces redundant, additive, or antagonistic effects is unknown.

Bioavailability and dosing. Community protocols report oral capsule doses of 50–150 mg/day. There is no published pharmacokinetic data establishing oral bioavailability or dose-response relationships in humans.

How it compares to other metabolic tools

The table illustrates the position of 5-amino-1MQ in this space: it sits at the far left of the evidence spectrum. The mechanism is interesting. The animal data is more consistent than most research chemicals in this category. The human data is zero.

That does not mean nobody is using it. The strength and biohacking community tends to move faster than the clinical trial system, using preclinical data plus community feedback as a partial substitute for RCT data. This is a reasonable pragmatic stance for some people and a poor one for others — it depends heavily on your personal risk tolerance and how much you weight theoretical mechanisms versus controlled evidence.

How 5-Amino-1MQ actually shows up in protocols

In user reports, 5-amino-1MQ typically appears in cutting protocols alongside a caloric deficit, training, and often other body-composition compounds (GH secretagogues, HGH fragment, peptides). Reported effects include modest improvements in fat loss rate and energy, though isolating the compound's contribution from the rest of the protocol stack is impossible from self-reports.

The oral capsule format makes it easy to add to a stack. There are no injections, no reconstitution, and no syringe management. This accessibility is part of why it's grown in popularity relative to injectable fat-loss peptides.

If you are considering it, the practical questions to have answers to:

• Are you running a verified caloric deficit? (No metabolic adjunct substitutes for energy balance)
• Have you sourced from a vendor with third-party testing? (Small molecule identity testing is relatively accessible — a certificate of analysis should be standard)
• Are you tracking any metabolic markers that would tell you if something is going wrong? (Fasting glucose, liver enzymes at minimum, given the unknowns around long-term NNMT inhibition)

For foundational context on evaluating research chemicals and reading sourcing documentation, see vendor due diligence and reading a certificate of analysis.

Related reading

• GH secretagogues for fat loss
• HGH fragment 176-191 fat loss
• Vendor due diligence checklist
• Side effects overview